Demant AS
DEMANT: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 464.00 | Cywkww | Scvyntjg |
Demant's Interim Results Show Strong Hearing Healthcare Recovery
We anticipate moderately increasing our fair value estimate for narrow-moat Demant following management’s interim statement. Management increased its fiscal 2021 EBIT outlook to DKK 3,300 million-3,500 million from DKK 3,150 million-3,450 million on the strength of the hearing business. We currently view the shares as modestly overvalued.